Poxvirus oncolytic virotherapy

Lino E. Torres-Domínguez, Grant McFadden

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Introduction: Over the last decade, advances in biological therapies have resulted in remarkable clinical responses for the treatment of some previously incurable cancers. Oncolytic virotherapy is one of these promising novel strategies for cancer therapy. A successful oncolytic virus promotes tumor cell oncolysis and elicits a robust long-term anti-tumor immunity. Areas covered: Oncolytic poxviruses (Vaccinia virus and Myxoma virus) demonstrated encouraging results in multiple pre-clinical tumor models and some clinical trials for the treatment of various cancers. This review summarizes the advances made on poxvirus oncolytic virotherapy in the last five years. Expert opinion: Many challenges remain in poxvirus oncolytic virotherapy. Two key goals to achieve are enhancing the efficiency of viral delivery to tumor sites and overcoming local tumor immune-evasion. Additional efforts are necessary to explore the best combination of virotherapy with standard available treatments, particularly immunotherapies. By addressing these issues, this new modality will continue to improve as an adjunct biotherapy to treat malignant diseases.

Original languageEnglish (US)
Pages (from-to)561-573
Number of pages13
JournalExpert Opinion on Biological Therapy
Issue number6
StatePublished - Jun 3 2019


  • Myxoma virus
  • Vaccinia virus
  • oncolytic
  • oncolytic virus
  • virotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Poxvirus oncolytic virotherapy'. Together they form a unique fingerprint.

Cite this